Acadia Pharmaceuticals | ACAD - Trade Debtors


Acadia Pharmaceuticals reported $166.33M in Trade Debtors for its fiscal quarter ending in June of 2026.





Trade Debtors Change Date
Acadia Pharmaceuticals USD 166.33M 17.95M Jun/2026
ALKERMES USD 456.48M 48.85M Jun/2026
Alnylam Pharmaceuticals USD 912.74M 28.78M Jun/2026
Biogen USD 1.79B 76.6M Mar/2026
BioMarin Pharmaceutical USD 1.06B 157.13M Jun/2026
Bristol-Myers Squibb USD 13.83B 535M Jun/2026
Cara Therapeutics USD 2.24M 2.26M Mar/2025
Corcept Therapeutics USD 76.92M 37.85M Jun/2026
Cytokinetics USD 6.83M 10.94M Mar/2026
Eisai JPY 253.13B 26.12B Jun/2026
Eli Lilly USD 23.48B 2.3B Jun/2026
Incyte USD 1.13B 73.7M Jun/2026
J&J USD 22.54B 1.21B Mar/2026
Moderna USD 17M 54M Jun/2026
Neurocrine Biosciences USD 887M 118.9M Jun/2026
Pfizer USD 16.19B 19M Jun/2026
Prothena USD 5.16M 0 Dec/2023
PTC Therapeutics USD 219.92M 38.3M Mar/2026
Sarepta Therapeutics USD 393.8M 154.11M Jun/2026
Ultragenyx Pharmaceutical USD 60M 98M Mar/2026
Vanda Pharmaceuticals USD 47.1M 4.35M Dec/2024
Vertex Pharmaceuticals USD 2.13B 138.2M Jun/2026